Mutated EGFR-IN-1

Mutated EGFR-IN-1 Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

N1-?[2-?(Dimethylamino)?ethyl]?-?5-?methoxy-?N1-?methyl-?N4-?[4-?(1-?methyl-?1H-?indol-?3-?yl)?-?2-?pyrimidinyl]?-?1,?2,?4-?benzenetriamine can be involved as reactant/reagent in "Schizophrenic" self-assembly of dual thermoresponsive block copolymers bearing a zwitterionic and a non-ionic hydrophilic block.

Mutated EGFR-IN-1 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Mutated EGFR-IN-1 Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Henan Fengda Chemical Co., Ltd	+86-371-86557731 +86-13613820652	info@fdachem.com	China	7377	58
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	sales@capotchem.com	China	29797	60
Shanghai Daken Advanced Materials Co.,Ltd	+86-371-66670886	info@dakenam.com	China	15371	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21695	55
Shanghai Yingrui Biopharma Co., Ltd.	+86-21-33585366 - 03@	sales03@shyrchem.com	CHINA	738	60
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32480	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Hangzhou Cyanochem Co., Ltd.	+86 17788583750	sales@cyanochem.com	CHINA	283	58
Jinan Finer Chemical Co., Ltd	+86-531-88989536 +86-15508631887	sales@finerchem.com	China	2966	58
Standardpharm Co. Ltd.	86-714-3992388	overseasales1@yongstandards.com	United States	14336	58

---

• Mutated EGFR-IN-1
• HY-78869
• AZD9291DA HCl salt
• N1-[2-(diMethylaMino)ethyl]-5-Methoxy-N1-Methyl-N4-[4-(1-Methyl-1H-indol-3-yl)-2-pyriMidinyl]benzene-1,2,4-triamine
• AZD9291 int-5
• N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-1,2,4-benzenetriamine
• 1,2,4-Benzenetriamine, N1-[2-(dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]-
• AZD9291 3
• N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine
• AZD9291 intermediate 4
• N1-(2-dimethylaminoethyl)-5-methoxy-N1-methyl-N4-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine
• N-(2-dimethylamino-ethyl)-2-methoxy-n-methyl-n-[4-(1-methyl-1h-indol-3-yl)-pyrimidin-2-yl]-5-Amino-benzene-1,4-diamine
• AZD9291 Intermediate1
• Mereletinib Intermediates
• OMT-3
• N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)b
• N1-(2-(Dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene
• AZD9291DA
• N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3- yl)pyrimidin-2-yl)benzene-1,2-triamine
• Osimertinib intermediate
• Osimertinib analog
• Mutated EGFR inhibitor 1
• AZD9291 intermediates 3
• Osimertinib Intermediate 3
• N1-[2-(Dimethylamino)ethyl]-5-methoxy-N1-methyl-N4-[4-(1-m-ethyl-1H-indol-3-yl)-2-pyrimidi-nyl]-1,2,
• Mutated EGFR-IN-1 (Osimertinib analog)
• AZD9291 N-2
• AZD91 intermediate
• CS-1173
• Osimertinib Impurity 5
• AZD9291 INT1 N-2
• 1-N-[2-(dimethylamino)ethyl]-5-methoxy-1-N-methyl-4-N-[4-(1-methylindol-3-yl)pyrimidin-2-yl]benzene-1,2,4-triamine
• AZD9291 intermediate
• N1- [2- (dimethylamino) ethyl] -5-methoxy-N1- methyl-N4- [4- (1-methyl-1H-indole-3-yl) -2-pyrimidinyl] -1,2,4-phenyltriamine
• Osimertinib N-2
• 1421372-66-8
• AZD9291
• Pharmaceutical intermediate
• API